 Fenofibrate
"Fenofibrate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood.
| Descriptor ID |
D011345
|
| MeSH Number(s) |
D02.241.081.114.968.500.625 D02.355.726.305.625 D02.455.426.559.389.134.750 D02.455.426.559.389.657.654.305.625 D02.522.223.750
|
| Concept/Terms |
Fenofibrate- Fenofibrate
- Phenofibrate
- Procetofene
- Procetofen
Apo-Feno-Micro- Apo-Feno-Micro
- Apo Feno Micro
- Apo-Fenofibrate
- Apo Fenofibrate
Lipanthyl- Lipanthyl
- Lipantil
- Fenofibrat FPh
- Lipidil
- Secalip
- Supralip
- Fénofibrate Debat
- Debat, Fénofibrate
- Lipidil-Ter
- Lipidil Ter
|
Below are MeSH descriptors whose meaning is more general than "Fenofibrate".
Below are MeSH descriptors whose meaning is more specific than "Fenofibrate".
This graph shows the total number of publications written about "Fenofibrate" by people in this website by year, and whether "Fenofibrate" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 2 | 1 | 3 | | 2005 | 1 | 0 | 1 | | 2007 | 2 | 1 | 3 | | 2009 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2012 | 2 | 0 | 2 | | 2013 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2017 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Fenofibrate" by people in Profiles.
-
Cheng L, Ge M, Lan Z, Ma Z, Chi W, Kuang W, Sun K, Zhao X, Liu Y, Feng Y, Huang Y, Luo M, Li L, Zhang B, Hu X, Xu L, Liu X, Huo Y, Deng H, Yang J, Xi Q, Zhang Y, Siegenthaler JA, Chen L. Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch Toxicol. 2018 Jan; 92(1):469-485.
-
Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, Lopez C, O'Connor PJ, Sweeney ME, Weiss D, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm R, Ismail-Beigi F, Goff DC, Fleg JL, Rosenberg Y, Byington RP. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. JAMA Cardiol. 2017 04 01; 2(4):370-380.
-
Boyle KE, Friedman JE, Janssen RC, Underkofler C, Houmard JA, Rasouli N. Metabolic Inflexibility with Obesity and the Effects of Fenofibrate on Skeletal Muscle Fatty Acid Oxidation. Horm Metab Res. 2017 Jan; 49(1):50-57.
-
Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, Genuth S, Goff DC, Leiter LA, Ismail-Beigi F, Ambrosius WT. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology. 2014 Dec; 121(12):2443-51.
-
Margolis KL, O'Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, Cutler JA, Evans GW, Gerstein HC, Grimm RH, Lipkin EW, Narayan KM, Riddle MC, Sood A, Goff DC. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014 Jun; 37(6):1721-8.
-
Walker AE, Kaplon RE, Lucking SM, Russell-Nowlan MJ, Seals DR. Response to effect of fenofibrate on vascular endothelial function: statistical appraisal and its validity. Hypertension. 2013 Jun; 61(6):e56.
-
Walker AE, Kaplon RE, Lucking SM, Russell-Nowlan MJ, Eckel RH, Seals DR. Fenofibrate improves vascular endothelial function by reducing oxidative stress while increasing endothelial nitric oxide synthase in healthy normolipidemic older adults. Hypertension. 2012 Dec; 60(6):1517-23.
-
Rasouli N, Kern PA, Elbein SC, Sharma NK, Das SK. Improved insulin sensitivity after treatment with PPAR? and PPARa ligands is mediated by genetically modulated transcripts. Pharmacogenet Genomics. 2012 Jul; 22(7):484-97.
-
Goldfine AB, Kaul S, Hiatt WR. Fibrates in the treatment of dyslipidemias--time for a reassessment. N Engl J Med. 2011 Aug 11; 365(6):481-4.
-
Perreault L, Bergman BC, Hunerdosse DM, Howard DJ, Eckel RH. Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans. Metabolism. 2011 Aug; 60(8):1107-14.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|